German drugmaker Boehringer Ingelheim has announced a management reshuffle to take place on Jan. 1, 2020.

The company has appointed Carine Brouillon, who currently oversees its therapeutics medications department, to be head of its overall pharma business as well as having a seat on the privately owned company’s board.

This change will follow the retirement of Allan Hillgrove, a 37-year Boehringer veteran who is responsible for the company’s human pharma and biopharma businesses, at the end of 2019.

Christian Boehringer, chairman of the shareholders’ committee, praised Hillgrove as having been critical in driving the drugmaker’s respiratory and diabetes portfolios to market, including the blockbuster diabetes medication Jardiance and idiopathic lung fibrosis drug Ofev.

Also to retire at the end of 2019 is Joachim Hasenmaier, who has led the company’s animal health business since 2001 and also served as head of consumer health care. The company credits him with helping forge key acquisitions, such as 2009's Fort Dodge buy.

New at the helm of animal health will be Jean Scheftsik de Szolnok, who will also join the board on what Boehringer said is an interim basis. The executive served as country managing director of France from September 2017.

In a final move, Andreas Neumann will step down from the board next month and leave the company after eight years. Boehringer is dividing human resources responsibilities between CEO Hubertus von Baumbach and CFO Michael Schmelmer.